Effectiveness of exercise therapy on improvement of quality of life in patients with parkinson disease

Assessment of effectiveness of short-term exercise therapy on functional capacity, balance and quality of life in patients with parkinson disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015062322891N1

Enrollment

Registered

2015-07-29

Start date

2015-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson disease. Parkinsonism or Parkinson disease

Interventions

Intervention 1: intervention name : Exercise Therapy and drug therapy intervention description : patients with mid phase PD that have been on drug treatment , Levodopa, will be undergone exercis

Treatment - Drugs

intervention name : Exercise Therapy and drug therapy intervention description : patients with mid phase PD that have been on drug treatment , Levodopa, will be undergone exercise therapy on tr

Interventopn name : drug therapy Control group : patiens wiyh midphase Parkinson disease are on Levodopa treatment

Eligibility

Sex/Gender

All

Age

30 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: diagnosed with Parkinson's Disease; being on phase (responsiveness to drug); being on moderate phase (UPDRS ). Exclusion criteria: freezing gait; atypical Parkinson syndrome (progressive supranuclear palsy, multiple system atrophy, drug-induced etc.); have more than 2 risk factor for cardiovascular disease; significant osteoporosis or arthritis; other neurological disease/complications (e.g. myopathy, stroke, brain lesion, MS); history of significant cardiovascular accident or MI.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Functional Capacity. Timepoint: 10 weeks after begining of trial , 2 and 4 month after finishing trial. Method of measurement: 6-minute Walk test , SF-8 quality of Life Questionairre.;Balance. Timepoint: 10 weeks from begining of trial , 2 and 4 month after trial. Method of measurement: Up and go test.;Quality of Life. Timepoint: 10weeks after begining of trial , 2 and 4 months after finishing the trial. Method of measurement: 8-SF Questionnaire Quality of Life.	—

Measure

Time frame

Functional Capacity. Timepoint: 10 weeks after begining of trial , 2 and 4 month after finishing trial. Method of measurement: 6-minute Walk test , SF-8 quality of Life Questionairre.;Balance. Timepoint: 10 weeks from begining of trial , 2 and 4 month after trial. Method of measurement: Up and go test.;Quality of Life. Timepoint: 10weeks after begining of trial , 2 and 4 months after finishing the trial. Method of measurement: 8-SF Questionnaire Quality of Life.

—

Secondary

Measure	Time frame
Activity of Daily Life. Timepoint: 2 and 4 months after study. Method of measurement: 6- minute walk test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParia Arfa Fattolahkhani

Iran university of medical sciences

arfa.paria.1571991@gmail.com+98 21 6651 2446

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026